Crossmark

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation

Published Online: 2022-08-02

Published Print: 2022-09

Authors

Odnopozova, Liudmila

Edin, Anton

Sukharev, Alexey

Wu, Tianshuang

Aydin, Kerstin

Kelly, Maureen

Khotko, Alkes
Funding

Funding for this research was provided by:

AbbVie
License Information

Text and Data Mining valid from 2022-08-02

Version of Record valid from 2022-08-02
More Information

Article History

Received: 3 May 2022

Accepted: 12 July 2022

First Online: 2 August 2022

Document is current